EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna: "PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older."
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment